Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a **Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy**

Fabien Zoulim¹, Vladimir Chulanov², Pietro Lampertico^{3,4}, Heiner Wedemeyer⁵, Adrian Streinu-Cercel^{6,7}, Victor Pantea⁸, Stefan Lazar⁹, George Sebastian Gherlan^{7,10}, Pavel Bogomolov¹¹, Tatyana Stepanova¹², Viacheslav Morozov¹³, Vladimir Syutkin¹⁴, Olga Sagalova¹⁵, Dmitry Manuilov¹⁶, Renee-Claude Mercier¹⁶, Lei Ye¹⁶, Grace M Chee¹⁶, Ben L Da¹⁶, Audrey H Lau¹⁶, Anu Osinusi¹⁶, Marc Bourlière¹⁷, Vlad Ratziu¹⁸, Stanilas Pol¹⁹, Marie-Noëlle Hilleret²⁰, Tarik Asselah²¹

ousse, Hospices Civils de Lyon, INSERM, Université Claude Bernard Lyon 1, Lyon, France; ²Sechenov University, Moscow, Russian Federation; ³Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Transplantation, Milan, Italy; ⁵Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie Hannover, Germany; ⁶Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; ¹⁰Dr. Victor Babes Foundation, Infectious and Tropical Diseases, Bucharest, Romania; ¹¹M.F. Vladimirsky Moscow, Russian Federation; ¹²LLC Clinic of Modern Medicine, Moscow, Russian Federation; ¹⁴M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁴M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁴M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁴M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁴M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁴M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁴M.F. Vladimirsky Moscow, Russian ¹³LLC Medical Company "Hepatolog," Samara, Russian Federation; ¹⁴Institute of Emergency Medicine n.a. NV Sklifosovsky, Moscow, Russian Federation; ¹⁴Institute of Emergency Medicine n.a. NV Sklifosovsky, Moscow, Russian Federation; ¹⁵South Ural State Medical Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Universite de Paris-Cité, INSERM, Clichy, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Universite de Paris-Cité, INSERM, Clichy, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Université de Paris-Cité, INSERM, Clichy, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Université de Paris-Cité, INSERM, Clichy, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Université de Paris-Cité, INSERM, Clichy, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Université de Paris-Cité, INSERM, Clichy, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Université de Paris-Cité, INSERM, Clichy, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²¹Hôpital Beaujon APHP, Universitaire Grenoble, France; ²⁰Centre Hospitalier Universitaire Grenoble, France; ²⁰

Conclusions

- In patients with CHD treated with BLV (2 mg or 10 mg) + Peg-IFN α , the key potential predictors of undetectable HDV RNA and the composite endpoint of undetectable RNA with ALT normalisation at EOT and in the posttreatment period were:
- Lower BL HDV RNA levels
- Lower BL liver stiffness
- In a subset of patients that achieved undetectable HDV RNA at EOT, key on-treatment predictors of non-relapse in the posttreatment period were:
- Earlier onset of undetectability
- Longer duration of undetectable HDV RNA status
- Achievement of early undetectable HDV RNA at week 24 on treatment is an important predictor of non-relapse in the posttreatment period

Plain Language Summary

- Chronic hepatitis delta, the most severe form of hepatitis, is a leading cause of advanced liver disease
- An undetectable level of hepatitis delta virus RNA early in treatment (week 24) is a predictor of maintained undetectable levels, an indication of treatment response, after the treatment period ends

References: 1. Alfaiate D, et al. J Hepatol. 2020;73(3):533-9. 2. Rizzetto M, et al. J Hepatol. 2021;74(5):1200-11. 3. Hepcludex. European Medicines Agency SmPC. Gilead Sciences, Inc; 2023. 4. Wedemeyer H, et al. Hepatology. 2023. doi: 10.1097/HEP.00000000000000584. 5. Asselah T, et al. AASLD 2023. Oral presentation #5009. 6. Roboscreen Diagnostics. https://www.roboscreen.com/products/viral-pathogens/robogene-hdv-rnaquantification-kit-20/

Acknowledgments: We extend our thanks to the patients, their families, and all participating investigators. This study was funded by Gilead Sciences, Inc. Editing and production assistance were provided by Samantha Tener, PhD, of AlphaScientia, a Red Nucleus company, and funded by Gilead Sciences, Inc.


Disclosures: FZ received consulting fees from Aligos Therapeutics; Antios Therapeutics; Assembly Biosciences; Gilead Sciences, Inc.; and GSK; and research funding to INSERM from Assembly Biosciences, Beam Therapeutics, and Janssen. VC reports consultant and sponsored lecture fees from AbbVie; AstraZeneca; Bristol Myers Squibb; Gilead Sciences, Inc.; GSK; Hepatera; Merck Sharp & Dohme; Roche; and R-Pharm. PL reports speaking and teaching fees from and participation in advisory committees or review panels for AbbVie; Aligos Therapeutics; Alnylam Pharmaceuticals; Antios Therapeutics; Arrowhead Pharmaceuticals; Bristol Myers Squibb; Eiger Biopharmaceuticals; Gilead Sciences, Inc.; GSK; Janssen; Merck Sharp & Dohme; MYR GmbH; Roche; and Spring Bank Pharmaceuticals. HW reports honoraria for speaking or consulting from Abbott; AbbVie; Boehringer Ingelheim; Bristol Myers Squibb; Eiger Biopharmaceuticals; Gilead Sciences, Inc.; Janssen; Merck Sharp & Dohme; MYR GmbH; Novartis; Novira; Roche; Roche Diagnostics; Siemens; and Transgene; and research support from Abbott; Bristol Myers Squibb; Gilead Sciences, Inc.; Novartis; Roche; and Roche Diagnostics. **MB** reports being a board member and speaker for AbbVie; Gilead Sciences, Inc.; Intercept Pharmaceuticals; and Roche. VR reports consultancy fees from Boehringer Ingelheim. TA acted as a speaker and investigator for AbbVie; Eiger Biopharmaceuticals; Gilead Sciences, Inc.; Janssen; Merck; MYR Pharmaceuticals; and Roche. DM, RCM, LY, GMC, BLD, AHL and AO are employees of Gilead Sciences, Inc., and may own stock in Gilead Sciences, Inc. ASC, VP, SL, GSG, PB, TS, VM, VS, OS, SP, and MNH report no conflicts of interest


- in the European Union³
- Chronic hepatitis delta (CHD) is the most severe form of viral hepatitis^{1,2} • Bulevirtide (BLV) 2 mg is approved for the treatment of compensated CHD
- with lower risk of disease progression⁴
- Achievement of hepatitis delta virus (HDV) RNA suppression is associated
- MYR204, a Phase 2b study (NCT03852433), evaluated finite treatment with BLV with or without pegylated interferon alfa-2a (Peg-IFN α)
 - response rates compared with either monotherapy regimen at 24 weeks after the end of treatment (EOT)⁵
- Combination treatment resulted in higher posttreatment virologic
- Potential predictors of on-treatment and posttreatment responses to combination therapy of BLV + Peg-IFNα are not yet characterised


Objective

Methods

- In this subanalysis, the logistic regression model was used to examine whether any BL or on-treatment clinical characteristics predicted treatment responses at EOT and follow-up at week 24 after EOT (FU-24) with combination therapy (arms B and C)
- Additional analysis of early on-treatment viral kinetics was performed on a subset of patients that achieved undetectable HDV RNA at EOT (predictors of non-relapse)








 Open-label, randomised, multicentre, Phase 2b study (NCT03852433) conducted at 19 sites across 4 countries (France, Moldova, Romania, and Russia)

Introduction

• To determine if any baseline (BL) characteristics or early on-treatment viral kinetics can predict EOT or posttreatment responses with combination treatment of BLV (2 or 10 mg) + Peg-IFNα





FU-48 in patients with undetectable HDV RNA. ^aHDV undetectability was defined as <LLOQ, TND via ultra-sensitive HDV PCR [RoboGene[®] 2.0, Roboscreen Diagnostics⁶]. LLOQ = 50 IU/mL;

<u>Composite response</u> was defined as undetectable HDV RNA and ALT normalisation. Viral relapse was defined as undetectable HDV RNA at EOT with detectable HDV RNA at 48 weeks off treatment

Subset for relapse analysis included patients who had undetectable HDV RNA at EOT and completed the study through the FU-48 visit. ADA, anti-drug antibodies; ALT, alanine aminotransferase; BL, baseline; BLV, bulevirtide; EOT, end of treatment; FU-24, follow-up at week 24 after EOT; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HDV, hepatitis delta virus; IFN, interferon; LLOQ, lower limit of quantification; Peg-IFNα, pegylated interferon alfa-2a; TND, target not detected.

Results





Baseline Disease Characteristics of Patients Treated With BLV in Combination With Peg-IFNα

	BLV 2 mg + Peg-IFNα n = 50	BLV 10 mg + Peg-IFNα n = 50
is, n (%)	17 (34)	17 (34)
nean (SD)	12.8 (6.4)	12.5 (7.6)
Pa, n (%)	9 (18)	7 (14)
	108 (77)	113 (98.6)
L, median (IQR)	5.6 (4.3–6.3)	5.5 (4.4–6.1)
	48 (96)	47 (94)
	1 (2) / 1 (2) / 0	2 (4) / 0 / 1 (2)
nean (SD)	3.7 (0.6)	3.7 (0.7)
_, mean (SD)	1.7 (1.6)	1.5 (1.1)
	41 (82)	38 (76)
%)	7 (14) / 40 (80) / 1 (2)	7 (14) / 38 (76) / 2 (4)
b)	42 (84)	47 (94)
(%)	25 (50)	26 (52)
dication, n (%)	24 (48)	25 (50)
bulevirtide: GT genotype: l	HRe∆a henatitis R e antigen: HRs∆a hen	atitis B surface antigen: HBV henatitis i

T, alanine transaminase; BLV, bulevirtide; GT, genotype; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HDV, hepatitis delta virus; ND, not determined; Peg-IFNa, pegylated interferon alfa-2a.

The BL disease characteristics were well balanced across both arms

 Both the 2- and 10-mg BLV dose levels in combination with Peg-IFNα demonstrated similar trends in off-treatment HDV RNA undetectability and composite response (data not shown)

 Among patients who achieved HDV RNA undetectability at EOT, the proportion of participants with viral relapse did not change between FU-24 and follow-up at week 48 after EOT (FU-48)

European Association for the Study of the Liver; 05–08 June 2024; Milan, Italy

Potential Predictors of Undetectable HDV RNA at EOT

Reference vs Comparison	n = 100	Odds Ratio (95% Cl)	Co
Treatment (BLV 10 m	g vs 2 mg)	3.0 (1.30, 6.76)	
Cirrhosis at BL (no vs yes)		3.6 (1.40, 8.90)	
BL ALT <1.5 × ULN vs ≥1.5 ×	ULN	1.9 (0.74, 4.67)	
BL HDV RNA <medianª td="" vs="" ≥median<=""><td></td><td>2.6 (1.10, 5.90)</td><td></td></medianª>		2.6 (1.10, 5.90)	
BL HDV RNA <q3⁵ td="" vs="" ≥q3<=""><td></td><td>3.8 (1.40, 10.26)</td><td></td></q3⁵>		3.8 (1.40, 10.26)	
Previous IFN therapy (no vs yes)		1.8 (0.76, 4.06)	
Concomitant HBV trea (no vs yes)	atment	2.1 (0.89, 4.77)	
BL platelet level >150 cells (10 ⁹ /L) vs ·	<100 (10º/L)	8.4 (0.82, 86.78)	
BL liver stiffness <11.1 kPa vs ≥11.1 kl	Pa	1.8 (0.80, 4.80)	
BL HBsAg log ₁₀ IU/ml	-	0.8 (0.37, 1.52)	

^aMedian = 5.54 log₁₀ IU/mL. ^bQ3 = 6.19 log₁₀ IU/mL HDV, hepatitis delta virus; IFN, interferon; Q, guartile; ULN, upper limit of normal.

Potential Predictors of Undetectable HDV RNA at FU-24

Reference vs Comparison	n = 100	Odds Ratio (95% Cl)	Co
Treatment (BLV 10 mg	vs 2 mg)	1.8 (0.80, 4.10)	
Cirrhosis at BL (no vs yes)		1.9 (0.78, 4.66)	
BL ALT <1.5 × ULN vs ≥1.5 × U	JLN	1.4 (0.59, 3.35)	
BL HDV RNA <medianª td="" vs="" ≥median<=""><td></td><td>4.5 (1.90, 11.00)</td><td></td></medianª>		4.5 (1.90, 11.00)	
BL HDV RNA <q3⁵ td="" vs="" ≥q3<=""><td></td><td>6.5 (1.80, 23.6)</td><td></td></q3⁵>		6.5 (1.80, 23.6)	
Previous IFN therapy (no vs yes)		2.4 (1.03, 5.50)	
Concomitant HBV treat (no vs yes)	ment	1.0 (0.46, 2.32)	
BL platelet level >150 cells (10 ⁹ /L) vs <1	100 (10º/L)	9.1 (0.37, 224)	
BL liver stiffness <11.1 kPa vs ≥11.1 kPa	a	2.4 (1.03, 5.60)	
BL HBsAg log ₁₀ IU/mL		0.4 (0.20, 0.88)	

ledian = 5.54 log₁₀ IU/mL. bQ3 = 6.19 log₁₀ IU/mL HBV, hepatitis B virus; HDV, hepatitis delta virus; IFN, interferon; Q, quartile; ULN, upper limit of normal


Reference vs Comparison	n = 51	Odds Ratio (95% CI)	C
Treatment (BLV 10 mg vs	s 2 mg)	1.1 (0.34, 3.64)	
Cirrhosis at BL (no vs yes)		1.5 (0.38, 5.95)	
BL ALT <1.5 × ULN vs ≥1.5 × ULI	N	1.5 (0.45, 4.93)	
BL HDV RNA <medianª td="" vs="" ≥median<=""><td></td><td>4.0 (1.15, 13.9)</td><td></td></medianª>		4.0 (1.15, 13.9)	
Previous IFN therapy (no vs yes)		1.9 (0.60, 6.21)	
BL HBsAg log ₁₀ IU/mL		0.4 (0.14, 1.30)	
Duration of HDV RNA undetectability (days)		1.006 (1.002, 1.010)	
Time to onset of first unde HDV RNA (days)	etectable	0.992 0.987, 0.997	
Week 16 HDV RNA unde (yes vs no)	tectable	8.8 (1.71, 44.9)	
Week 24 HDV RNA unde (yes vs no)	tectable	19.1 (3.62, 100.7)	
Week 48 HDV RNA unde (yes vs no)	tectable	5.6 (1.38, 22.7)	


The red box highlights potential predictors that are characteristics of on-treatment viral kinetics. ^aMedian = 5.09 \log_{10} IU/mL. ALT, alanine aminotransferase; BL, baseline; BLV, bulevirtide; EOT, end of treatment; FU-48, follow-up at week 48 after EOT; HBsAg, hepatitis B surface antigen; HDV, hepatitis delta virus; IFN, interferon; OR, odds ratio; Q, quartile; ULN, upper limit of normal.

FRI-371

and/or text key codes are t








ALT, alanine aminotransferase; BL, baseline; BLV, bulevirtide; EOT, end of treatment; FU-24, follow-up at week 24 after EOT; HBsAg, hepatitis B surface antigen;

undetectable HDV RNA at EOT were: — The absence of cirrhosis. HDV RNA levels that were

Potential BL predictors of

- less than the median and less than quartile (Q) 3 and lower liver stiffness measurements
- Results were driven by the dose level of BLV (10 mg)
- Data trends were similar when BLV 10 mg was given alone: BL HDV RNA levels (odds ratio: 4.3, p = 0.035)and lower BL liver stiffness (odds ratio: 5.3, p = 0.015)
- Similar trends were observed for the composite endpoint (data not shown)
- Potential BL predictors of undetectable HDV RNA at FU-24 were:
- HDV RNA levels that were less than the median and <Q3, lower HBsAg levels, no previous IFN therapy, and lower liver stiffness measurements
- Previous IFN therapy was not a predictor of composite response at FU-24, while other trends were similar (data not shown)

Potential Predictors of Non-Relapse at FU-48 in Patients With Undetectable HDV RNA at EOT



- Potential predictors of nonrelapse at FU-48 in patients with undetectable HDV RNA at EOT were:
- BL HDV RNA levels that were less than the median, and shorter time to onset and longer duration of HDV RNA undetectability on treatment
- Of note, 23 of 25 patients with undetectable HDV RNA at week 24 on treatment did not relapse by FU-48